Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2008.

"We made significant progress in both of our development programs during the first quarter," said Steve Worland, Ph.D., President and CEO of Anadys. "We successfully completed preclinical evaluation of ANA598, our non-nucleoside polymerase inhibitor for the treatment of hepatitis C, and have subsequently filed an IND for this product candidate. We also commenced dosing with ANA773, our oral TLR7 agonist prodrug, in patients with advanced cancer." Providing an updated cash outlook for 2008, Dr. Worland added, "Based on promising results from the preclinical evaluation of ANA598, we have made the strategic decision to accelerate certain non-clinical development activities for ANA598 into 2008 and now expect our cash utilization this year to be in the range of $29 million to $31 million."

Financial Results

As of March 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $48.8 million compared to $56.5 million as of December 31, 2007.

During the first quarter of 2008 the Company had no revenue, compared to $1.1 million in revenue for the same quarter of 2007. The revenue in the first quarter of 2007 was primarily derived from the amortization of an upfront payment and milestone payment under a prior collaboration.

Research and development expenses were $6.0 million for the first quarter of 2008 compared to $6.7 million for the first quarter of 2007. The $0
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... XR(TM) rosacea-specific study also slated for presentation at American ... NAPA, Calif., March 5 Senetek PLC (OTC ... the development of technologies that target the science of ... launching at the American Academy of Dermatology,s 67th Annual ...
... AMSTERDAM, March 5 ,Agendia, a world leader in ... Albert A. (Al) Luderer to its Supervisory Board. ... more than 30 years of experience in in ... he,is the Chief Executive Officer and President of ...
... Fla., March 5 NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), ... for the fourth quarter and full-year ended December 31, 2008. ... Revenue of $5.9 million, an increase ... 17.2% sequential increase in revenues in Q4 08 vs. Q3 08 ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 3NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 4NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 5NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 6NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 7NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 8
(Date:7/29/2014)... book that brings together two of the major disciplines ... of insect fossils through stunning photographs and unique illustrations. ... E Jepson, details the incredible preservation and diversity of ... for what these remarkable fossils can tell us about ... of our planet. Like the mosquito in Jurassic Park, ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
(Date:7/28/2014)... professor John Essigmann and colleagues from the University of Washington ... if they could induce the virus to mutate uncontrollably, they ... a strategy that our immune system uses against many viruses. ... HIV to mutate at an enhanced rate, as expected. But ... small clinical trial reported in 2011. In a new study, ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... Researchers at the Virginia Bioinformatics Institute at Virginia Tech and ... at 454 Life Sciences of Branford, Conn., have sequenced the ... is a naturally occurring strain of B. abortus ... John Buck in 1923. It has been used for more ...
... eastern spinner dolphins in the eastern tropical Pacific Ocean ... death in the tuna purse-seine fishery between 1960 and ... "These estimates are encouraging because they are consistent ... stocks are recovering, now that reported fishery mortality has ...
... the strange properties of quantum mechanics to the macroscopic ... series of recent developments. The exciting progress was made ... recently at a high level conference organised by the ... Frderung der wissenschaftlichen Forschung in sterreich (FWF) and the ...
Cached Biology News:Brucella abortus S19 genome sequenced; points toward virulence genes 2NOAA study shows eastern tropical pacific ocean dolphin populations improving 2Europe gets together to harness quantum physics 2Europe gets together to harness quantum physics 3Europe gets together to harness quantum physics 4
... serum biomarker chip to profile the relative ... chip containing 120 human cancer serum biomarker-specific ... discovery scientists to study panels of biomarkers ... and the likelihood of recurrence of cancer. ...
... is a highly sensitive reagent for the ... a purified form of recombinant E. coli ... which is sensitive to changes in its ... Phosphate Sensor is rapid and tight (Kd ...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: